Anxiety Disorders Terminated Phase 3 Trials for Imagabalin (DB12105)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00836069Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety DisorderTreatment